This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Stephen Russell, M.D., Ph.D.
Professor of Molecular Medicine at Mayo Clinic

Profile

Stephen J. Russell  M.B.Ch.B., Ph.D., FRCP (UK), FRCPath (UK), LLD (Hon).

Stephen J. Russell MD PhD, Founder, Director, CEO & President

Dr. Russell is a Professor of Molecular Medicine, Consultant Hematologist at Mayo Clinic Rochester and serves on the Board of Trustees of Buena Vista University, Iowa. He obtained his MD from the University of Edinburgh, Scotland and his PhD from the University of London, England. He trained at University College Hospital and the Royal Marsden Hospital, London, then moved to Cambridge, England where he led a research team in the MRC Laboratory for Molecular Biology and was a practicing consultant hematologist at Addenbrooke’s Hospital. In 1998 he moved to Mayo Clinic where he built a comprehensive translational gene and virus therapy program, established the Department of Molecular Medicine, developed innovative technologies for targeting viruses to cancer cells, and orchestrated the first-in-human testing of oncolytic Measles and Vesicular stomatitis viruses. In addition to his academic faculty role, he is currently serving as CEO of Vyriad, an oncolytic virotherapy company and is President Elect for the American Society of Gene and Cell Therapy.


His research is focused on developing engineered viruses for the treatment of disseminated malignancies and demonstrating their efficacy in clinical trials. Research themes in his laboratory include the engineering of viral membrane glycoproteins, targeting cell to cell fusion, targeting virus entry, using cellular microRNAs to reprogram virus tropism, modulating and exploiting virus-tumor-immune system interactions, pharmacokinetic and pharmacodynamic studies of virus-based therapies, noninvasive monitoring and imaging of viral gene expression in vivo, and radiovirotherapy.

Agenda Sessions

  • Advances in T-Cell Engaging Therapies

    12:30
  • Lentiviral Vectors Stealthed for In Vivo T cell Transduction and Retargeted via Surface Display of a CD3-Specific scFv

    On Demand